How Schaefer was paid
$469,001 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Total |
|---|---|---|---|---|
| Thomas J. SchaeferPresident and Chief Executive Officer | $260,000 | $169,000 | $40,001 | $469,001 |
| Mark KawakamiFormer Chief Financial Officer | $178,424 | — | $40,001 | $218,425 |
What changed and why
- $469K$469,001 was the CEO’s 2025 total compensation, compared with $499,477 in 2024.
- $169K$169,000 was the CEO’s 2025 discretionary bonus, while no Executive Incentive Bonus Plan bonuses were paid.
- $40,001$40,001 in option awards was reported for both named executive officers in 2025.
- $218K$218,425 was former CFO Mark Kawakami’s 2025 total compensation.
- September 12, 2025 was the effective date of Kawakami’s resignation as officer and employee.
- Four-year vesting applied to the 12,500-share options granted to each executive in 2025.
Other Arcadia Biosciences proxy statements
- 2025 proxy statement
Thomas J. Schaefer paid $499,477 (+31% on the year).
Filed Nov 19, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.